|
1
|
Blechacz BR and Gores GJ:
Cholangiocarcinoma. Clin Liver Dis. 12:131–150, ix. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wiangnon S, Suwanrungruang K and Kamsa-Ard
S: Cholangiocarcinoma in Khon Kaen Province. Srinagarind Med J. 27
suppl:(Cholangiocarcinoma). S326–S330. 2012.
|
|
3
|
Sripa B, Bethony JM, Sithithaworn P,
Kaewkes S, Mairiang E, Loukas A, Mulvenna J, Laha T, Hotez PJ and
Brindley PJ: Opisthorchiasis and Opisthorchis-associated
cholangiocarcinoma in Thailand and Laos. Acta Trop. 120 Suppl
1:S158–S168. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sripa B, Kaewkes S, Sithithaworn P,
Mairiang E, Laha T, Smout M, Pairojkul C, Bhudhisawasdi V, Tesana
S, Thinkamrop B, et al: Liver fluke induces cholangiocarcinoma.
PLoS Med. 4:e2012007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Debruyne PR, Bruyneel EA, Li X, Zimber A,
Gespach C and Mareel MM: The role of bile acids in carcinogenesis.
Mutat Res 480–481. 1–369. 2001.
|
|
6
|
Changbumrung S, Tungtrongchitr R, Migasena
P and Chamroenngan S: Serum unconjugated primary and secondary bile
acids in patients with cholangiocarcinoma and hepatocellular
carcinoma. J Med Assoc Thai. 73:81–90. 1990.PubMed/NCBI
|
|
7
|
Werneburg NW, Yoon JH, Higuchi H and Gores
GJ: Bile acids activate EGF receptor via a TGF-alpha-dependent
mechanism in human cholangiocyte cell lines. Am J Physiol
Gastrointest Liver Physiol. 285:G31–G36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alpini G, Kanno N, Phinizy JL, Glaser S,
Francis H, Taffetani S and LeSage G: Tauroursodeoxycholate inhibits
human cholangiocarcinoma growth via Ca2+−, PKC-, and MAPK-dependent
pathways. Am J Physiol Gastrointest Liver Physiol. 286:G973–G982.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scalia S and Games DE: Determination of
free bile acids in pharmaceutical preparations by packed column
supercritical fluid chromatography. J Pharm Sci. 82:44–47. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roda A, Piazza F and Baraldini M:
Separation techniques for bile salts analysis. J Chromatogr B
Biomed Sci Appl. 717:263–278. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Humbert L, Maubert MA, Wolf C, Duboc H,
Mahé M, Farabos D, Seksik P, Mallet JM, Trugnan G, Masliah J and
Rainteau D: Bile acid profiling in human biological samples:
Comparison of extraction procedures and application to normal and
cholestatic patients. J Chromatogr B Analyt Technol Biomed Life
Sci. 899:135–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Steiner C, von Eckardstein A and Rentsch
KM: Quantification of the 15 major human bile acids and their
precursor 7α-hydroxy-4-cholesten-3-one in serum by liquid
chromatography-tandem mass spectrometry. J Chromatogr B Analyt
Technol Biomed Life Sci. 878:2870–2880. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sugita T, Amano K, Nakano M, Masubuchi N,
Sugihara M and Matsuura T: Analysis of the serum bile acid
composition for differential diagnosis in patients with liver
disease. Gastroenterol Res Pract. 2015:7174312015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang A, Sun H, Yan G, Han Y, Ye Y and
Wang X: Urinary metabolic profiling identifies a key role for
glycocholic acid in human liver cancer by ultra-performance
liquid-chromatography coupled with high-definition mass
spectrometry. Clin Chim Acta. 418:86–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee BL, New AL and Ong CN: Comparative
analysis of conjugated bile acids in human serum using
high-performance liquid chromatography and capillary
electrophoresis. J Chromatogr B Biomed Sci Appl. 704:35–42. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Olsson R: Ursodeoxycholic acid in the
treatment of chronic cholestatic liver disease. Documented delay in
disease progress inspires hope. Lakartidningen. 99:1325–1330.
2002.(In Swedish).
|
|
17
|
Poupon R, Chazouillères O and Poupon RE:
Chronic cholestatic diseases. J Hepatol. 32 1 Suppl:S129–S140.
2000. View Article : Google Scholar
|
